Clinical Trial

A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2025 (before its estimated July 22, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, open-label, single-center clinical trial designed to evaluate the efficacy and safety of fruquintinib in combination with a PD-1 inhibitor and chidamide in patients with refractory MSS-type metastatic colorectal cancer (mCRC). A total of 46 patients are planned to be enrolled, with the primary endpoint being median progression-free survival (mPFS). Secondary endpoints include median overall survival (mOS), objective response rate (ORR), and safety.
Trial Details
NCT Number NCT06979908
Lead Sponsor The First Hospital of Jilin University
Conditions Metastatic Colorectal Cancer
Enrollment 46 participants
Start Date 2025-01-22
Primary Completion 2026-07-22 (estimated)
Study Completion 2027-01-22 (estimated)
Updated on ClinicalTrials.gov 2025-05-20